ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

22,872Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 105

$981K Total Retail Price of All Prescriptions

Rank: 2 out of 105

1,245 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
44% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

0% of this provider’s 17,972 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $47 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
ISOSORBIDE MONONITRATE ER 2,131 1,696 10 1 9
CARVEDILOL 1,567 1,146 2 3
PRAVASTATIN SODIUM 1,565 1,265 10 3 11
AMLODIPINE BESYLATE 1,541 1,229 4 2
ENALAPRIL MALEATE 1,098 857 5 32
HYDROCHLOROTHIAZIDE 1,088 856 6 17
CLOPIDOGREL 969 800 7 8
METOPROLOL SUCCINATE 857 653 8 6
METOPROLOL TARTRATE 821 651 9 4
NITROSTAT 761 595 10 10 23
SIMVASTATIN 758 536 11 5
PLAVIX 727 593 12 10
LISINOPRIL 562 416 13 1
FUROSEMIDE 546 373 14 7
LOSARTAN POTASSIUM 466 365 15 18
AMIODARONE HCL 430 401 16 21
ATORVASTATIN CALCIUM 419 343 17 13
HYDRALAZINE HCL 353 294 18 43
ATENOLOL 344 261 19 14
RANEXA 335 247 20 22
POTASSIUM CHLORIDE 308 211 21 15
OMEPRAZOLE 268 180 22 29
CRESTOR 225 188 23 19
WARFARIN SODIUM 218 191 24 12
DIOVAN 198 191 25 28
BENICAR 197 167 26 52
MULTAQ 167 140 27 51
TEKTURNA 148 136 28 78
LEVOTHYROXINE SODIUM 138 134 29 38
DILTIAZEM ER 137 122 30 31
GEMFIBROZIL 137 72 30 67
CHLORTHALIDONE 121 99 32 62
SPIRONOLACTONE 114 83 33 20
BENICAR HCT 110 92 34 57
DILTIAZEM 24HR CD 109 83 35 34
PRADAXA 106 97 36 25
BYSTOLIC 103 97 37 26
DILTIAZEM 24HR ER 96 91 38 85
PACERONE 93 82 39 49
LOSARTAN-HYDROCHLOROTHIAZIDE 91 67 40 35
FOSINOPRIL SODIUM 90 74 41 99
MICARDIS 85 65 42 101
DIOVAN HCT 75 70 43 58
LIPITOR 74 52 44 46
TRIAMTERENE-HCTZ 72 61 45 39
NIFEDIPINE ER 72 46 45 41
LISINOPRIL-HYDROCHLOROTHIAZIDE 69 59 47 24
LOVASTATIN 68 37 48 53
ZETIA 65 30 49 45
COUMADIN 65 64 49 72
NIASPAN 63 46 51 48
DIGOXIN 60 39 52 16
FENOFIBRATE 58 40 53 54
TRICOR 55 44 54 116
BENAZEPRIL HCL 54 38 55 80
SOTALOL 53 53 56 27
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 15, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.